ClinicalTrials.gg
RecruitingNCT07595068US-RESTUpdated Aug 21, 2026

Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases

An interventional study of Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion and Sham low-intensity focused ultrasound targeting the left stellate ganglion in Atrial Fibrillation (AF) and Cardiovascular Diseases, sponsored by Renmin Hospital of Wuhan University. Recruiting at 7 sites in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Renmin Hospital of Wuhan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
139th of 256
200 · median 235
Started
2026
with 47 others
No phase
200 of 377
100 open now
Primary completion
2027-04
later than 105 of 182 live
Registered
345th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 139th largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 105 of the 182 other live ones, and was the 345th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for improving autonomic function and sleep quality in perioperative cardiovascular disease patients.

The main questions it aims to answer are:

  1. Does LIFU improve heart rate variability and sleep characteristics from baseline at 3-7 days post-surgery compared to sham ultrasound?
  2. Does LIFU improve serological markers, vital signs, Pittsburgh Sleep Quality Index (PSQI), and reduce >30-second perioperative arrhythmias?
  3. What is the safety profile of LIFU in this population? 200 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min daily for 3-7 days) plus standard care, or identical sham ultrasound plus standard care. A four-party double-blind design (subjects, operators, assessors, analysts) will be implemented. The study will run from May 1, 2026 to April 1, 2027 at 6 centers in China.

Participants will:

  1. Complete pre-surgery screening and baseline assessments (PSQI, 12h ECG/sleep monitoring, residual blood sample collection)
  2. Receive daily assigned ultrasound intervention for 3-7 consecutive days post-surgery
  3. Undergo 72h continuous ECG monitoring post-surgery, and repeat assessments at 3-7 days
  4. Have all adverse events and arrhythmias recorded throughout the study
  5. May withdraw voluntarily at any time without affecting routine medical care
03

Conditions studied

  • Atrial Fibrillation (AF)
  • Cardiovascular Diseases

Keywords

  • Low-Intensity Focused Ultrasound
  • Cardiovascular Diseases
  • Stellate Ganglion
  • Autonomic Nervous Function
  • Sleep Quality
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with cardiovascular disease (CVD) and scheduled to undergo cardiology-related surgical treatment
  2. Able to receive and tolerate the aforementioned cardiology-related surgical treatment
  3. Aged between 18 and 79 years (inclusive), with no restriction on gender
  4. Agree to accept random allocation of the treatment strategies
  5. With clear consciousness, no severe mental disorders or cognitive impairment; voluntarily sign the written form (ICF) and are willing to actively cooperate with the study treatment

Exclusion criteria

Exclusion Criteria:

  1. Have used sedative-hypnotic drugs, antipsychotic drugs, opioid analgesics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), central nervous system (CNS) stimulant drugs, or any other medications that alter sleep architecture within the past 30 days
  2. Have a history of cervical infection, trauma, severe cervical deformity, or prior cervical surgery
  3. Unable to complete the daily study intervention as required by the trial protocol
  4. Are participating in another clinical trial, or have participated in other clinical trials with interventions that may interfere with the results of this study
  5. Have undergone major surgery or general anesthesia within the past 30 days
  6. Have a history of alcohol abuse
  7. Are female subjects who are pregnant or lactating, or plan to become pregnant during the study period
  8. Have severe cognitive impairment, severe psychiatric disorders, epilepsy, or other related neurological disorders
  9. Have concomitant malignant tumor or severe dysfunction of vital organs
  10. Have active systemic infection
  11. Have significant bleeding tendency, or renal failure undergoing regular hemodialysis
  12. Are deemed unsuitable for the trial by the investigator for any other reason -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Low-Intensity Focused Ultrasound (LIFU) Intervention Arm

    Subjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention on the left stellate ganglion. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session, once daily for 3-7 consecutive days. All subjects will receive guideline-concordant standard perioperative cardiovascular care, including surgery and indicated medications.

    Device: Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion

  • Placebo comparator
    Sham Ultrasound Control Arm (Placebo)

    Subjects in this arm will receive sham ultrasound intervention with identical operational procedures, device appearance, and parameter settings (no actual energy output) as the intervention arm. Sessions are once daily for 3-7 consecutive days. All subjects will receive the same guideline-concordant standard perioperative cardiovascular care as the intervention arm.

    Device: Sham low-intensity focused ultrasound targeting the left stellate ganglion

Interventions

  • DeviceLow-intensity focused ultrasound (LIFU) targeting the left stellate ganglion

    The experimental group receives active low-intensity focused ultrasound (LIFU) treatment: the ultrasound probe is placed on the skin surface corresponding to the left stellate ganglion and fixed with a mechanical arm, with parameters set as power 2.0W, frequency 1MHz, duty cycle 50%, 30 minutes per session, once daily for 3-7 consecutive days. All enrolled subjects receive standard perioperative cardiovascular care simultaneously throughout the study period.

  • DeviceSham low-intensity focused ultrasound targeting the left stellate ganglion

    The control group receives sham low-intensity focused ultrasound intervention: the ultrasound probe is placed on the skin surface corresponding to the left stellate ganglion and fixed with a mechanical arm, with the same instrument appearance, operation process, parameter setting display (power 2.0W, frequency 1MHz, duty cycle 50%), duration (30 minutes per session, once daily for 3-7 consecutive days) and subject experience as the experimental group, but no actual ultrasound energy is output. All enrolled subjects receive standard perioperative cardiovascular care simultaneously throughout the study period.

06

What researchers measure

Primary outcomes

  1. SDNN

    Standard deviation of all normal-to-normal intervals measured by wearable Holter monitor; Unit: ms; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  2. Total sleep duration

    Total sleep time measured by wearable sleep monitor; Unit: hours; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  3. SDANN

    Standard deviation of the averages of NN intervals in all 5-minute segments; Unit: ms; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  4. SDNN Index

    Mean of the standard deviations of all NN intervals for all 5-minute segments; Unit: ms; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  5. RMSSD

    Root mean square of successive differences between normal heartbeats; Unit: ms; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  6. pNN50

    Percentage of successive NN intervals that differ by more than 50 ms; Unit: %; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  7. LF power

    Low frequency power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  8. HF power

    High frequency power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  9. TP

    Total power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  10. LF/HF ratio

    Ratio of low frequency to high frequency power; Unit: ratio; Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  11. Wakefulness percentage

    Percentage of time awake during sleep period; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  12. Insomnia percentage

    Percentage of time with insomnia symptoms during sleep period; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  13. REM sleep percentage

    Percentage of rapid eye movement sleep during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  14. N1 sleep stage percentage

    Percentage of N1 sleep stage during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  15. N2 and N3 sleep stages percentage

    Combined percentage of N2 and N3 sleep stages during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  16. Sleep efficiency

    Ratio of total sleep time to time in bed; Unit: %; Measurement device: Wearable sleep monitor.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

Secondary outcomes

  1. IL-1β level

    Serum IL-1β concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  2. Norepinephrine (NE) level

    Serum norepinephrine concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  3. Brain-derived neurotrophic factor (BDNF) level

    Serum brain-derived neurotrophic factor concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  4. Pittsburgh Sleep Quality Index (PSQI) score

    Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index questionnaire; Unit: Score on a 0-21 scale, where higher scores indicate worse sleep quality; Method of Measurement: Self-administered questionnaire.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  5. Number of atrial arrhythmias

    Measurement: count of atrial arrhythmia episodes. Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  6. Duration of atrial arrhythmias

    Measurement: Duration of atrial arrhythmia episodes. Measurement device: wearable Holter monitors.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  7. TNF-α level

    Serum TNF-α concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  8. Neuropeptide Y (NPY) level

    Serum neuropeptide Y concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

  9. Melatonin level

    Serum melatonin concentration; Unit: pg/mL.

    Time frame: Pre-operative 24 hours and Post-operative 72 hours

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Due to considerations for protecting participant privacy, undetermined data ownership, or the absence of a detailed data-sharing policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 19, 2026
StartActual
May 20, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07595068
Lead sponsor
Renmin Hospital of Wuhan University
Collaborators
Yichang Central People's Hospital, Wuhan Central Hospital, Huangshi Central Hospital, Wuhan Third Hospital, Xiangyang Central Hospital, Jingzhou Central Hospital
Responsible party
Songyun Wang (Associate Chief Physician & Associate Professor, Renmin Hospital of Wuhan University) — Principal investigator
First posted
May 19, 2026
Start date
May 20, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Songyun Wang, MD
Contact
wsy7982@126.com
+86 13871262107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion